Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL5870476 | 1.00 | CYP2C9 (0.34) | CYP2C9MAPTALDH1A1LMNAINPP5A | |
| Sulfuric Acid SCHEMBL5870480 | 1.00 | CYP2C9 (0.34) | CYP2C9MAPTALDH1A1LMNAINPP5A | |
| Sulfuric Acid SCHEMBL5870557 | 0.89 | HTT (0.40) | CYP2C9MAPTLMNAINPP5AHPGD | |
| Sulfuric Acid SCHEMBL5870555 | 0.89 | HTT (0.40) | CYP2C9MAPTLMNAINPP5AHPGD | |
| SCHEMBL3963226 | 0.88 | NOS3 (0.33) | CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL3965893 | 0.88 | NOS3 (0.33) | CYP2C9MAPTALDH1A1LMNA | |
| Sulfuric Acid SCHEMBL3965247 | 0.85 | INPP5A (0.41) | MAPTINPP5AKDM4EHPGD | |
| SCHEMBL5870459 | 0.76 | CYP1A2 (0.46) | CYP2C9MAPTLMNAHPGDTLR4 | |
| SCHEMBL20980563 | 0.75 | CA1 (0.38) | CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL12441371 | 0.75 | CA1 (0.38) | CYP2C9MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | CYP2C9 1036/4885MAPT 4248/4885ALDH1A1 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.